Vontobel Holding’s ProQR Therapeutics PRQR Stock Holding History

Vontobel Holding’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-63,979	Closed	-$131K	–	1415
2025 Q2	$131K	Buy	63,979 +27,722	+76%	+$45.1K	﹤0.01%	1203
2025 Q1	$48.2K	Buy	+36,257	New	+$77.2K	﹤0.01%	1062
2024 Q2	–	Sell	-10,000	Closed	-$22.7K	–	1134
2024 Q1	$22.7K	Hold	10,000	–	–	﹤0.01%	1073
2023 Q4	$19.8K	Hold	10,000	–	–	﹤0.01%	1087
2023 Q3	$13K	Hold	10,000	–	–	﹤0.01%	1062
2023 Q2	$16.2K	Hold	10,000	–	–	﹤0.01%	1091
2023 Q1	$21.3K	Buy	+10,000	New	+$30.6K	﹤0.01%	1061

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vontobel Holding's PRQR Position: Q3 2025 in Review

Vontobel Holding sold out of ProQR Therapeutics (PRQR) in Q3 2025, closing a stake of 63,979 shares — an estimated $131K sold.

Vontobel Holding first reported a position in PRQR in Q1 2023 and held it in 7 quarters. The position peaked at $131K in Q2 2025. 64 funds tracked by Wall St. Rank hold PRQR as of Q3 2025.

Vontobel Holding reported no remaining ProQR Therapeutics position as of Q3 2025 after selling out during the quarter.
Vontobel Holding sold 63,979 ProQR Therapeutics shares in Q3 2025, an estimated $131K.
Vontobel Holding first reported a position in ProQR Therapeutics in Q1 2023 and held it in 7 quarters.
Vontobel Holding's ProQR Therapeutics position peaked at $131K in Q2 2025.
64 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2025.

Based on Vontobel Holding's 13F filing for Q3 2025, filed 15 Oct 2025.